PennyStocksUpdate.biz is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
New York, NY -- (SBWIRE) -- 03/13/2013 -- Camelot Information Systems Inc. (NYSE:CIS) is a holding company that conducts business, through its operating subsidiaries in China. Camelot is a domestic provider of enterprise application services and financial industry information technology (IT) services in China. Its service lines include enterprise application services (EAS), which consist of packaged software services for enterprise resource planning (ERP) software packages, and software development and maintenance services, and financial industry IT services (FIS), which consist of software solutions, system support and maintenance, as well as IT consulting services for the financial industry.
Shares of Camelot Information (NYSE: CIS) are trading at $1.69 and is +20.08% of its 50-day Moving Average price of $1.4074 and +18.42% from its 200-day Moving Average price of $1.4272. The average trading volume is 170463 shares and its market capitalization is $75.0M.
How Should Investors React To CIS Now? Find Out Here
Mellanox Technologies, Ltd. (NASDAQ:MLNX) a fabless semiconductor company that produces and supplies interconnect products for computing, storage, and communication applications in the computing, Web 2.0, storage, financial services, database, and cloud markets is currently up (+6.36%) on 949,980 shares traded after Mellanox and DataDirect Networks to Host Webinar on Scalable Infrastructure Solutions for Increasing Next-Gen Communications Provider ROI, Tuesday, March 12, 2013. Mellanox Technologies, Ltd. (NASDAQ: MLNX) are currently up (+74.39%) from its recent 52-week low which has prompted Growing Stock Report to add the stock to their NASDAQ Gainers Watch List.
Click Here to find out what other Investors are saying about Mellanox Technologies, Ltd. (NASDAQ:MLNX)
Opexa Therapeutics, Inc. (NASDAQ:OPXA) a biopharmaceutical company that engages in the development of patient-specific cellular therapies for the treatment of autoimmune diseases is currently up (+10.94%) on 788,583 shares traded. Opexa Therapeutics, Inc. (NASDAQ:OPXA) is currently up (+104.67%) from its recent 52-week low which has prompted Growing Stock Report to add the stock to their NASDAQ Gainers Watch List.
Click Here to find out what other Investors are saying about Opexa Therapeutics, Inc. (NASDAQ:OPXA)
BioScrip Inc (NASDAQ:BIOS) shares climbed 8.26 percent to $11.80 in post-market trading Monday. BioScrip reported adjusted EPS income of $0.04 per share, beating the mean analyst estimate of $0.01. Its revenues stood at $180.7 million from the year earlier quarter, topping the average revenue estimate of $173.87 million.
Click Here to find out what other Investors are saying about BioScrip Inc. (NASDAQ:BIOS)
Neither PennyStocksUpdate.biz nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by PennyStocksUpdate.biz, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.PennyStocksUpdate.biz makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through PennyStocksUpdate.biz. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)